A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

454

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG: Trastuzumab Deruxtecan
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pembrolizumab
DRUG: Pemetrexed

Sponsor

AstraZeneca

Collaborators

[object Object]